Genetic Design and Manufacturing Corporation (GDMC), a design and manufacturing organization that focuses on next generation advanced genetic therapies, secured a Series A funding of $21 million, led by Celadon Partners, an Asia private equity firm.

The funds will be used to accelerate novel technology and process efficiency improvements to drive greater manufacturing cost reductions for partners who aim to advance medicines through clinical trials and towards commercialization.

“The process of manufacturing a genetic medicine is extremely intricate and demands a specialized and highly knowledgeable team to successfully bring it to fruition. We are grateful to our investors for their support in realizing our vision of democratizing the manufacturing of advanced genetic medicines while leveling the playing field for innovative companies and leaders in advanced therapies,” said Michael Koeris, CEO and co-founder of GDMC. “With our recent funding, we aspire to cultivate stronger collaborations with more partners in the U.S. and Asia-Pacific (APAC) region, working hand in hand to improve the state of healthcare and treatment for patients.”

GDMC was established in 2021 by Koeris, an entrepreneur with over two decades of experience in the biotech and healthcare sectors. The team comprises experienced drug makers and contract development and manufacturing organization (CDMO) commercialization experts including Eric Blair, GDMC’s chief business officer, who brings 25 years of experience in commercializing products and CDMO services through partnerships.

The company’s headquarters is in Singapore, where GDMC has initiated construction on a 155,000 square foot pre-clinical, clinical, and commercial facility supporting cell, gene, and nucleic acid therapies (CGNT). GDMC’s partnership approach is centered on improving genetic medicine design and development through synthetic biology, as well as focusing on three market-relevant pillars: success-based partnerships with sponsors, technical innovation, and lower cost of goods. According to the company, it has signed their first clients and are taking reservations for the clinical and commercial facilities expected to open in a staggered format from 2024 to 2027.